Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent and Shenogen to Test PD-1/Brain Cancer Candidate Combo

publication date: Aug 6, 2019

Suzhou's Innovent Bio will collaborate with Beijing Shenogen Pharma to test a combination of Innovent's approved PD-1 drug, Tyvyt® with Shenogen's SNG1005 in patients with advanced cancer. SNG1005 is a conjugate of angiopep-2 and paclitaxel that is designed to cross the blood-brain barrier. Shenogen has been approved to conduct a China Phase II/III trial of SNG1005 in patients with breast cancer carcinoma brain metastases (BCBS). In late 2018, Tyvyt® was approved in China to treat classical Hodgkin's lymphoma. Innovent develops biologics for oncology, while Shenogen is a discovery/development pharma. More details....

Stock Symbol: (HKEX: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.